Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 12, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Primary endpoint of induction of amenorrhea met for both vaginal doses compared to placebo, p<0.0011Proellex®-treated subjects reported a median 100% reduction in diary reports of menstrual...
March 15, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

THE WOODLANDS, Texas, March 15, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has formally activated the process for obtaining marketing authorization...
March 14, 2016 09:15 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results

THE WOODLANDS, Texas, March 14, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the fourth quarter and year ended December 31, 2015. ...
February 16, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Phase 2 proof of concept study in obese men to assess drug impact on metabolic and quality of life parameters under a rigorous diet and exercise regimen Analyses at 3, 6 and 12 month time...
February 08, 2016 16:01 ET | Source: Repros Therapeutics Inc.

Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

THE WOODLANDS, Texas, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that on February 4, 2016, the Company attended a productive meeting with FDA...
January 11, 2016 09:15 ET | Source: Repros Therapeutics Inc.

Repros Announces Court of Appeals’ Affirmation of Summary Judgment in Favor of the Company

THE WOODLANDS, Texas, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the United States Court of Appeals for the Federal Circuit summarily affirmed...
January 04, 2016 16:05 ET | Source: Repros Therapeutics Inc.

Repros Updates Enclomiphene Program

Repros expects to meet with FDA to discuss “Complete Response Letter” for enclomiphene NDA during February 2016Marketing Authorization Application (MAA) for enclomiphene planned for submission in...
December 21, 2015 16:05 ET | Source: Repros Therapeutics Inc.

Repros Updates Proellex® Program

Topline results after first four months of treatment from all three Proellex® trials expected to be available by end of Q3’16Screening for low dose study for oral Proellex® for uterine fibroids...
December 01, 2015 09:50 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

THE WOODLANDS, Texas, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it has received a Complete Response Letter from the U.S. Food and Drug...
November 12, 2015 16:05 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding

THE WOODLANDS, Texas, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has completed randomization for its Phase 2b study of Proellex® in the...